CABALETTA BIO, INC. Finance Lease, Right-of-Use Asset, Amortization
CABALETTA BIO, INC. (CABA) reported Finance Lease, Right-of-Use Asset, Amortization of $3.10 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2025-03-31
- CABALETTA BIO, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $3.10M.
- CABALETTA BIO, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $0.00.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|
| 2024-12-31 | $3.10M 10-K · filed 2025-03-31 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |